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Background: Epidemiological studies report high rates of depression among patients with cystic fibrosis (CF).
Assuming a causal relationship between depression and the progression of CF, our hypothesis is that elevated
symptoms of depression would be a predictor of worse lung function after two years.
Methods: In the context of the TIDES study, 473 German patients with CF (age 12–53 years, FEV1% predicted
M = 66.2, range 13–137) completed the Hospital Anxiety and Depression Scale (HADS). Lung function (FEV1%
predicted) was assessed at baseline and followed up two years later. Repeated measures analysis was performed
involving the level of FEV1% and the level of depressive symptoms at baseline as independent factors and FEV1%
at the 2-year follow-up as the dependent variable.
Results: Interaction between lung function and depression at baseline significantly affected the change in lung
function at the 2-years observation interval. The largest decline in FEV1% occurred in depressed patients with good
lung function at baseline. In contrast, patients without any clinically relevant depressive symptoms and with poor
lung function at baseline showed a slight increase two years later.
Conclusion: The findings emphasise the need to screen patients with CF for symptoms of depression and to treat
co-morbid depression.
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Forced expiratory volume in one second (FEV1%) is the
key outcome in cystic fibrosis (CF) for monitoring the
course of the disease [1]. Average rates of annual decline
in FEV1% are reported to be between one and three per
cent [2,3]. A range of biological risk factors such as in-
fection with Pseudomonas aeruginosa or pancreatic
insufficiency promote this decline [3-6]. Moreover, asso-
ciations between pathophysiological processes, such as
inflammation, and increased symptoms of depression
were identified in the context of other medical condi-
tions [7-9]. In addition, psychological factors might ex-
plain additional variance in the course of the disease,
given their association with adherence to treatment.* Correspondence: astrid.fidika@uniklinik-ulm.de
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unless otherwise stated.Prevalence rates for depression range between 6.9%
in Europe [10] and 8.6% in the US [11]. They therefore,
point to a major public health issue worldwide. Re-
cently, a German study found that nine per cent of ado-
lescent and adult patients with CF show clinically
relevant symptoms of depression, similar to the preva-
lence in the general population [12]. According to the
international TIDES study involving nine countries
[13], 10% of adolescents and 19% of adults with CF re-
ported elevated symptoms of depression. It is important
to address depression in the context of medical treat-
ment for two reasons. First, depression is a recognised
major mental health problem and is associated with
poor quality of life [14]. Evidence-based treatments for
depression are available [15,16] and patients with CF
should be given an opportunity to access these treat-
ments. Depression is a known risk factor for poor ad-
herence to treatment more particularly in the case ofhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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patients who screened positive for symptoms of depres-
sion have a three-fold higher risk of not adhering to
some degree to their medical treatment [18]. Symptoms
of depression such as low mood, lack of energy or
hopelessness may impair the patient’s willingness and
ability to adhere to his medical treatment plan. Self-
monitoring of CF-symptoms may be limited owing to
depression and patients may find it difficult to identify
situations where medical assessment and intervention
would be appropriate. Poor adherence to the medical
regime limits treatment effectiveness, promotes disease
progression and may, ultimately, reduce survival [19].
Accordingly, previous research showed that the mental
health state of patients with chronic lung diseases does
indeed impact relevant medical outcomes. Patients with
asthma or chronic obstructive pulmonary disease have
better disease outcomes in the absence of co-morbid
anxious or depressive disorders [20-22]. Likewise in pa-
tients with CF symptoms of depression are inversely as-
sociated with lung function [12,22]. Hence, patients with
severely impaired lung function reported the highest
levels of symptoms of depression. In a recent study the
decrease in lung function over a 12 year period was as-
sociated with a deterioration in health-related quality of
life (HrQoL). This is known to be inversely correlated
with depression [23]. Another study found that specific
HRQoL domains, i.e. the pain domain in the SF-36
questionnaire and the physical functioning domain in
the Cystic Fibrosis Quality of Life Questionnaire, con-
tributed prospectively to the prediction of the survival of
adults with CF [24].
Summarizing the evidence from epidemiological stud-
ies, it could be argued that progression of CF drives co-
morbid depression. However, the association between
depression and the course of the CF may be reciprocal
but so far there have been no longitudinal studies that
disentangled this relationship in patients with CF. To
further investigate the association between depression
and lung function in patients with CF, we prospectively
examined the hypothesis that symptoms of depression
would be a predictor lung function in a two-year follow-
up assessment when controlling for baseline disease se-
verity of the CF-related lung disease.Methods
Participants and procedure
Self-reported symptoms of depression were assessed in
the German arm of the international epidemiological
study on depression and anxiety in patients with CF
(TIDES) [12]. These data were used as baseline mea-
sures for the current longitudinal study. Medical data
at baseline and two years later were retrieved from thepatients’ medical charts as documented in the German
CF registry.
All patients consented to participate in this TIDES
study and to the use of their individual medical data
from the German CF registry. The IRB at the University
of Ulm approved the study.
612 of the 670 patients participating in the German
arm of the TIDES study, were treated in German CF
centres and their data were stored in the German regis-
try. Complete baseline data, which included HADS de-
pression score and lung function, were available for 575
of these patients. As follow-up data on lung function
two years later were not available for all patients, the
study sample for the current longitudinal analysis com-
prised 473 patients. No information was available about
reasons for follow-up losses, such as death of a patient.
No differences in FEV1% at baseline were observed be-
tween the patients with complete follow-up data and
non-complete data (t = −1.61; df = 573; p = .108) or for
symptoms of depression (t = −1.95; df = 573; p = .052).
Measures
Demographic and FEV1% data
Demographic information (age, gender, professional sta-
tus, and living situation) and FEV1% were retrieved from
the annual reports of the CF clinics to the German CF
registry. The FEV1% value closest to the patient’s birth-
day was used as the indicator of lung function.
Symptoms of depression
Symptoms of depression were measured using the de-
pression subscale of the Hospital Anxiety and Depres-
sion Scale (HADS) [25], a brief and easy-to-administer
screening tool for assessing symptoms of anxiety and de-
pression in medical populations. Any physical symptoms
of depression confounding with a chronic illness, such
as fatigue or headaches, were excluded. For the prior
seven-day period, patients rate the magnitude of each
symptom of seven core symptoms of depression on a
four-point scale ranging from 0 to 3. Raw scores are
added and established cut-off scores distinguish between
normal (0–7 points), borderline (8–10 points), and clin-
ical symptom levels (≥11 points) [25,26]. Many studies
that use the HADS confirmed that it is valid for both
clinical and community settings. Good psychometric
properties have been demonstrated [26,27] for the
German version, too [28].
Statistical analyses
First, all data were analysed descriptively. Frequencies of
cases with elevated symptoms of depression using the
established cut-off score (8 or higher) [25,28] were
computed.
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cording to the status of depression and disease severity at
baseline, a 2×2 repeated measures ANOVA was conducted
with lung function at baseline (FEV1% ≤40% vs. >40%) and
depression at baseline (HADS depression 0 to 7 vs. 8 or
higher) as independent variables, and lung function
(FEV1% predicted) at follow-up as a dependent variable.
Cut-offs for classification of FEV1% as severely limited
range from 30% to 50%. We chose the cut-off of ≤40%, be-
cause it indicates a significant airflow limitation and is
commonly used in other studies. Effect sizes (η2) were
computed (η2 > 0.01 indicating small, η2 > 0.10 medium,
and η2 > 0.25 large effects) [29].
As regression to the mean (RTM) is a relevant cause of
misinterpretation of results based on repeated measures,
we investigated RTM quantification in accordance with
Barnett et al. [30]. Because the group of patients with and
the group without elevated symptoms of depression
showed a significant difference in their mean FEV1% at
baseline (t = 8.29; p < .001), we computed RTM effects
separately for both groups and then checked these results
against the means of the change scores (follow-up FEV1%-
baseline FEV1%) of the four sub-groups.
All statistical analyses were performed with IBM Sta-
tistics SPSS 20.0 for Windows.Results
Characteristics of the study sample
The age of the patients at baseline assessment ranged from
12 to 53 years (M = 23.2, SD = 8.6); 55.4% were male. Most
of the patients were living with their family or their part-
ner (79.3%) and were in education or employment (in
school 27%, in job training 35.5%, employed 21.9%, un-
employed 5.1%, retired 10.4%).
The patients’ lung function data at baseline are pre-
sented in Table 1. Altogether, 38 (8%) patients reported
elevated levels of depression, with 21 (4.4%) of them in
the borderline range at baseline. 89 (18.8%) patients had
a severe lung disease at baseline (FEV1% ≤ 40). Patients
with elevated symptoms of depression differed signifi-
cantly in their FEV1% (depressed: M = 44.33, SD = 16.01Table 1 Lung function (FEV1%) at baseline among the




















Range 13.7-137.3 23.1-39.0 13.7-39.7 40.4-76.5 40.1-137.3
M 66.2 32.2 31.4 59.6 74.8
SD 24.7 4.8 6.5 11.1 20.0
≤40% 89 (18.8%)
>40% 384 (81.2%)vs. not depressed: M = 68.06, SD = 24.39; t = 8.292;
p < .001) from the patients with no elevated symptoms.
Depression and course of FEV1%
As expected, a significant main effect of time (F = 5.96;
p = .015; η2 = 0.013) indicated an average decrease of about
3% in the FEV1 predicted in our study sample during the
two year observation period (Figure 1). A significant effect
of group affiliation (F = 118.18; p < 0.001; η2 = 0.43) is inci-
dental due to the fact that FEV1% predicted was one base-
line criterion for classification.
A significant group x time interaction effect (F = 5.44;
p = .001; η2 = 0.034) reveals that in the four groups lung
function changed differently over time. The mean lung
function decreased in three of the four groups. The largest
group, i.e. patients with moderate to good lung function
without symptoms of depression at baseline, declined
from 74.9% (SD = 20.0) to 70.9% (SD = 22.1) during the
two years under observation. Depressed patients with
moderate or good lung function at baseline showed the
greatest decline of all four groups from an average of
59.6% (SD = 11.1%) at baseline to 52.0% (SD = 20.7%) two
years later. Patients with poor lung function and symp-
toms of depression at baseline decreased on average a fur-
ther 3.5% from 32.2% (SD = 4.8) to 28.7% (SD = 4.9).
Contrary to the expectations, severely ill patients without
depression at baseline increased slightly from 31.2% (SD =
6.5) to 34.3% of the FEV1 predicted (SD = 17.09).
The estimated RTM effect was +/−1.06 for the groups of
patients with symptoms of depression within the normal
range (n = 435). It was +/− 2.66 for the group with elevated
symptoms of depression (n = 38). The observed average
changes within the groups were higher than this score for
each of the four corresponding subgroups: FEV1% ≤ 40, de-
pressed (M = −3.41; SD = 5.26), FEV1% ≤ 40, normal (M =
2.86; SD = 18.28), FEV1% > 40, depressed (M = −7.03; SD =
16.75), and FEV1% > 40, normal (M = −3.87; SD = 12.36).
Discussion
This is the first study to examine the impact of depres-
sion on change in lung function, especially FEV1% pre-
dicted, in adolescents and adults with CF. The results
show that clinically relevant symptoms of depression
may increase the loss of lung function and that severely
ill patients without depression are able to improve their
lung function against the progressive trend of CF. There-
fore, in a bio-psycho-social model depression should be
considered as an important risk factor for disease pro-
gression in patients with CF. This backs the position that
mental health is a relevant factor as already mentioned
in the literature in conjunction with other chronic con-
ditions that impair the respiratory system [20-22]. Given
our prospective study design, assumptions may be made





































Figure 1 Change of FEV1% predicted over the period of two years, analyzed by level of lung function and state of depression at
baseline (n = 473).
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ing results was taken into account. The estimated effects
of RTM in the groups were lower than the observed
changes in lung function. We can therefore, conclude
that our findings are not solely based on RTM.
Our results are consistent with a theoretical model about
the relationship between adherence, self-management be-
haviours and disease outcomes outlined by Modi et al.
[31]. The interaction between depression and disease pro-
gression could be linked to the lack of hope, optimism and
perceived self-efficacy in depressed patients, consequently
inhibiting their fighting spirit against the disease and ne-
cessary adherence to treatment. Thus, depressed patients
may fail to respond to standard medical treatment due to
the nature of their mental health problems, and may ex-
perience a greater loss of lung function than necessary.
This effect may then reinforce the negative thoughts re-
lated to their own prognosis, triggering a vicious psycho-
somatic cycle. In contrast, patients who are not depressed
and already have severely restricted lung function might be
more able to make use of resources for their daily treat-
ment routines. This, in turn, might result in stable or even
slightly improved outcomes.
Despite the strengths of this study, such as the rela-
tively large sample size and the prospective design allow-
ing for causal conclusions, some limitations may have
biased our results. Due to study participants who were
lost for follow-up for unknown reasons, a selection bias
may have occurred in our results. However, our sub-
group comparisons in what is still a relatively large sam-
ple for a rare condition like CF constitute a sound
empirical basis for our results. The collection of data
was based on registry data which may lead to limitations
in interpretation [32]. More particularly, information
about lung function (FEV1% predicted) is not fully avail-
able over the two-year period in the registry because it isdocumented as a single-point measure in the observed
year. This may cause higher individual variations than
when using means or longitudinal data per year and
does not allow for consideration of variability in patient
lung function. Given the small number of patients in
the groups, we were not able to control for confounders,
such as CF-related diabetes or status of colonisation
with germs. This, too, could perhaps had provided some
substantial information to help explain the variance in
the course of lung function within our sample. Due to
the lack of feasibility in a routine clinical setting, symp-
toms of depression were assessed by self-reports only,
and the persistence of these symptoms was not assessed.
The use of HADS has been discussed controversially
within the TIDES study [13]. The questionnaire was de-
veloped for use in medical settings and was deemed to
be a valid and reliable screening measure when planning
the TIDES study [26,27]. However, more recent studies
report several shortcomings, such as underestimation of
symptoms of depression [33,34]. Other valid and reliable
screening questionnaires, such as PHQ-9 [33,35], might
be a better choice for future studies and for use as a
screening tool, as recently recommended by the Inter-
national Guidelines Committee on Mental Health for
Patients with CF and Their Caregivers [36]. Additionally,
the generalisation of our results to patients in other
countries warrants future investigation.
Conclusions
Our findings have several important clinical implica-
tions. Previous studies established that although there
are substantial rates of co-morbid symptoms of depres-
sion in adolescent and adults with CF, not all patients
receive treatment [12,22]. The current findings indicate
that it is important to identify depressed patients and to
offer them mental healthcare. Systematic screening
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their depression should become an essential component
in the care of patients with CF, as recently recom-
mended by the International Guidelines Committee on
Mental Healthcare for Patients with CF and Their
Caregivers [36]. The Committee was sponsored by the
European CF Society and the CF Foundation of the US
and stressed the importance of targeting symptoms of
depression and anxiety through appropriate interven-
tion. Considering the importance of depression which
is again emphasised by the results of the current study,
treatment goals should include stabilisation of the pa-
tients' mood, behavioural activation, and the creation
of a sense of self-efficacy.
Since no evidence-based interventions seeking to de-
crease the symptoms of depression specifically in pa-
tients with CF are available at the present time [22,37],
those psychotherapeutic and psychopharmacological
treatments known to be effective for patients with a pri-
mary diagnosis of depression should also be applied to
patients with CF. However, in psychopharmacological
treatment, possible reciprocal effects between CF medi-
cation and medication for depression have to be consid-
ered. Research efforts are needed to identify effective
strategies for the delivery of treatments for depression in
patients with CF, and to evaluate their risks and benefits.
Furthermore, strategies to help patients keep their lung
function stable or even improve it might be an interest-
ing topic for further studies in order to learn more about
resources and successful coping strategies. Further re-
search on the long-term effects of co-morbid depression
and their impact on disease progression could be worth
examining, for instance to establish whether they are of
equal prognostic value for survival.Competing interests
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